Adynxx (ADYX) 10-Q 9 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 03, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		29,674,087

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 12,572	$ 26,080
Accounts receivable, net	2,514	2,060
Inventory, net	3,128	2,275
Prepaid expenses and other current assets	646	942
Current assets of discontinued operations	533	1,315
Amount due from sale of assets	4,103	0
Total current assets	23,496	32,672
Improvements and equipment, net	2,291	1,847
Intangible assets, net	31,926	33,667
Goodwill	21,166	21,166
Other assets	173	173
Assets of discontinued operations - noncurrent	0	227
Total assets	79,052	89,752
Current Liabilities:
Accounts payable	2,117	2,594
Accrued expenses and other current liabilities	3,042	3,071
Contingent consideration, current	1,359	2,573
Current portion of long-term debt, net	1,780	0
Warrant liability	199	861
Current liabilities of discontinued operations	111	103
Total current liabilities	8,608	9,202
Long-term debt, net	10,776	12,126
Contingent consideration, long-term	1,792	14,455
Deferred tax liability	1,474	1,468
Other long-term liabilities	361	76
Total liabilities	23,011	37,327
Commitments and Contingencies
Stockholders’ Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 29,674,609 and 27,668,913 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively	30	28
Additional paid-in capital	154,581	148,457
Accumulated deficit	(98,570)	(96,060)
Total stockholders’ equity	56,041	52,425
Total liabilities and stockholders’ equity	$ 79,052	$ 89,752

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	29,674,609	27,668,913
Common stock, shares outstanding	29,674,609	27,668,913

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue, net of returns, allowances and discounts	$ 4,467	$ 2,488	$ 8,424	$ 4,049
Cost of revenues	1,599	1,190	3,189	2,223
Gross profit	2,868	1,298	5,235	1,826
Operating expenses
Selling, general and administrative	9,551	8,230	19,509	14,508
Research and product development	328	279	527	300
Acquisition-related	0	915	0	2,861
Change in fair value of contingent consideration liability	(9,092)	265	(8,730)	373
Total operating expenses	787	9,689	11,306	18,042
Income (loss) from operations	2,081	(8,391)	(6,071)	(16,216)
Other income (expense)
Interest expense	(653)	(233)	(1,271)	(233)
Interest income	7	13	15	19
Change in fair value of warrant liability	(75)	(90)	662	(78)
Total other expense	(721)	(310)	(594)	(292)
Income (loss) from continuing operations before tax	1,360	(8,701)	(6,665)	(16,508)
Income tax (expense) benefit	(3)	1,440	(6)	1,437
Income (loss) from continuing operations	1,357	(7,261)	(6,671)	(15,071)
Discontinued operations:
Income from discontinued operations, net of tax of $0 for the three and six months ended June 30, 2016 and 2015	504	271	850	420
Gain on sale of assets, net of tax of $0 for the three and six months ended June 30, 2016 and 2015	3,311	0	3,311	0
Income from discontinued operations, net of tax	3,815	271	4,161	420
Net income (loss)	$ 5,172	$ (6,990)	$ (2,510)	$ (14,651)
Net income (loss) per basic common share:
Income (loss) from continuing operations	$ 0.05	$ (0.33)	$ (0.24)	$ (0.68)
Income from discontinued operations	0.02	0.01	0.03	0.02
Gain on sale of assets	0.11	0	0.12	0
Total	0.13	0.01	0.15	0.02
Net income (loss) per basic common share	0.18	(0.32)	(0.09)	(0.66)
Net income (loss) per diluted common share:
Income (loss) from continuing operations	0.05	(0.33)	(0.24)	(0.68)
Income from discontinued operations	0.02	0.01	0.03	0.02
Gain on sale of assets	0.11	0	0.12	0
Total	0.13	0.01	0.15	0.02
Net income (loss) per diluted common share	$ 0.18	$ (0.32)	$ (0.09)	$ (0.66)
Weighted average shares used in computing net income (loss) per common share:
Basic	28,169,843	22,108,703	27,731,465	22,103,377
Diluted	28,568,600	22,108,703	27,731,465	22,103,377

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	$ 0	$ 0	$ 0

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Activities
Net loss	$ (2,510)	$ (14,651)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,085	832
Amortization of deferred lease incentive	(19)	(4)
Deferred income tax expense (benefit)	6	(1,437)
Provision for doubtful accounts	31	46
Provision for excess and slow moving inventory	3	13
Stock-based compensation expense	3,080	4,323
Deferred rent	75	0
Amortization of debt issuance and debt discount costs	428	85
Change in fair value of warrant liability	(662)	78
Fair value adjustment of contingent consideration liability	(8,730)	373
Gain on sale of assets	(3,311)	0
Changes in operating assets and liabilities:
Accounts receivable	(560)	(533)
Inventory	(601)	(1,122)
Prepaid expenses and other current assets	294	(15)
Accounts payable	(473)	345
Accrued expenses and other current liabilities	413	(691)
Net Cash Used in Operating Activities	(10,451)	(12,358)
Investing Activities
Purchase of improvements and equipment	(484)	(77)
Acquisition of business, net of cash acquired	0	(14,948)
Net Cash Used in Investing Activities	(484)	(15,025)
Financing Activities
Contingent purchase price payments	(2,573)	0
Net proceeds from issuance of common stock	0	32,197
Net proceeds from long-term debt	0	14,244
Proceeds from the exercise of stock options	0	300
Payment of withholding taxes related to stock-based employee compensation	0	(369)
Net Cash (Used in) Provided by Financing Activities	(2,573)	46,372
Net (Decrease) Increase in Cash and Cash Equivalents	(13,508)	18,989
Cash and Cash Equivalents - Beginning of period	26,080	16,771
Cash and Cash Equivalents - End of period	12,572	35,760
Supplemental Disclosure of Cash Flows Information
Interest	842	148
Non-cash investing and financing activities:
Extinguishment of warrant liability due to cashless warrant exercise	0	31
2015 Accrued bonus awarded in equity	474	0
Common stock issued for contingent purchase price payments	2,574	0
Acquisition of business:
Current assets, excluding cash and cash equivalents	0	1,836
Intangibles	0	31,952
Goodwill	0	16,825
Liabilities assumed	0	(2,006)
Deferred tax liability	0	(2,881)
Contingent consideration	0	(15,570)
Issuance of common stock for acquisition	$ 0	$ (15,208)

Description of Business and Bas

Description of Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a provider of advanced wound care solutions. The Company has a suite of advanced wound care solutions that enable surgeons, clinicians, and wound care practitioners to address some of the challenges presented by chronic and advanced wounds. The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2016 and results of operations and cash flows for the three and six months ended June 30, 2016. The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation. Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported. As of June 30, 2016, the Company had cash and cash equivalents and working capital of approximately $ 12.6 14.9 10.5 2.6 1.4 The Company’s cash requirements have historically been for mergers and acquisitions, product development, clinical trials, marketing and sales activities, finance and administrative costs, capital expenditures and working capital. Since inception, the Company has incurred negative cash flows and has funded operations primarily from the sales of common stock and other securities. On June 30, 2016 the Company sold the rights to the sorbion product for total consideration of approximately $ 4.1 3.5 1.8 Due to the time delay between collection of revenues and the initial outlays for costs for acquiring rights to additional products, the hiring and training of sales agents and personnel, marketing, purchasing inventory, billing and collection of revenue, conducting a post market clinical trial for Biovance, servicing debt, and due diligence related to merger and acquisition activities, the Company expects to continue to have a cash outflow until it has a significant increase in revenue, achieves profitability or raises additional financing. If the Company is unable to achieve profitability, raise additional financing or extend the time or manner of the final installment of the contingent consideration, it will need to develop and implement an alternative plan to extend payables, reduce operating costs and/or scale back planned business operations until sufficient capital is raised to support its business plans. There can be no assurance that such a plan will be successful. In addition, the Company’s credit agreement requires it to meet certain financial covenants. Failure to observe or perform any covenant contained in the credit agreement would result in the event of default. If an event to default were to occur, payment of the remaining principal amount of approximately $ 13.7 The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the condensed consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements.

Net Loss Per Common Share

Net Loss Per Common Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	2. Net Loss Per Common Share Basic income (loss) per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted income (loss) per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Numerator: Net income (loss) from continuing operations (numerator for basic and diluted earnings per share) $ 1,357 $ (7,261) $ (6,671) $ (15,071) Weighted average shares outstanding (denominator for basic earnings per share) 28,169,843 22,108,703 27,731,465 22,103,337 Effect of dilutive securities: Assumed vesting of restricted stock, treasury stock method 398,757 - - - Dilutive potential common shares 398,757 - - - Denominator for diluted earnings per share- weighted average shares and assumed potential common shares 28,568,600 22,108,703 27,731,465 22,103,337 Basic earnings (loss) from continuing operations per share $ 0.05 $ (0.33) $ (0.24) $ (0.68) Diluted earnings (loss) from continuing operations per share $ 0.05 $ (0.33) $ (0.24) $ (0.68) Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Options 7,427,279 6,073,740 7,427,279 6,073,740 Warrants 3,365,407 3,372,550 3,365,407 3,372,550 Non-vested restricted stock 460,001 784,076 1,480,041 784,076 Total potentially dilutive shares 11,252,687 10,230,366 12,272,727 10,230,366

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3. Acquisitions Acquisition of Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds for an aggregate purchase price of approximately $ 46.3 15.5 0.3 3,168,229 15.6 The Company has agreed to pay contingent consideration of 3.5 The first installment consisted of $ 2.6 986,000 2.6 10.2 8.7 As of June 30, 2016, the Company has recorded a liability of approximately $ 2.8 At the date of acquisition and June 30, 2016, the cash flow projection was discounted using a weighted average cost of capital of 12.5 These fair value measurements were based on significant inputs not observed in the market and thus represented a Level 3 measurement. Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for the three and six months ended June 30, 2015, as if the acquisition had been completed as of January 1, 2015. The pro forma results were calculated applying the Company’s accounting policies and include the effects of adjustments related to the amortization charges from the acquired intangibles and long-term debt. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had actually occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future. Three Months Ended Six Months Ended Revenues $ 4,362 $ 8,138 Net loss $ (10,835) $ (21,128) Net loss per share $ (0.43) $ (0.84)

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	4. Discontinued Operations Asset Sale In order to add capital and to focus on future investments on commercializing its own highly differentiated advanced wound care and regenerative technologies effective June 30, 2016, the Company entered into a purchase agreement (the “Purchase Agreement”) with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN (i) all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights (collectively, the “Rights”) to the sorbion product line pursuant to its distribution agreement (as amended, the “Sorbion Agreement”) with Sorbion GmbH & Co KG and (ii) the unsold inventory of sorbion products previously purchased by the Company) in existence as of the closing, which occurred upon execution and delivery of the Purchase Agreement. In consideration for the sale of the Rights and the unsold sorbion inventory to BSN by the Company, 3.5 900,000 to the unsold sorbion inventory upon the Company’s completion of its obligations to deliver all remaining and qualifying unsold sorbion inventory, with such payment amount varying based upon the condition of the sorbion inventory, as specified in the Purchase Agreement 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311 On June 30, 2016, the Company entered into a ninety-day transition services agreement with BSN (“Transition Agreement”). Under the Transition Agreement, the Company shall perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the business to BSN, as specified in the Transition Agreement. As compensation, BSN shall pay the Company $ 100,000 Discontinued Operations Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue, net of returns, allowances and discounts $ 1,023 $ 648 $ 1,709 $ 1,201 Cost of revenues 348 184 536 358 Gross profit 675 464 1,173 843 Selling, general and administrative 171 193 323 423 Income from discontinued operations, net of tax 504 271 850 420 Non-cash amortization expense of $ 38,000 June 30, December 31, 2016 2015 Accounts receivable, net $ 533 $ 457 Inventory, net - 858 Total current assets 533 1,315 Intangible assets, net - 227 Total assets 533 1,542 Accounts payable 48 44 Accrued expenses and other current liabilities 63 59 Total current liabilities $ 111 $ 103

Inventory

Inventory	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. Inventory June 30, December 31, 2016 2015 Raw materials $ 213 $ 241 Work in process 255 228 Finished goods 2,722 1,865 Less: Inventory reserve for excess and slow moving inventory (62) (59) Total $ 3,128 $ 2,275

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets June 30, 2016 Useful Life Gross Accumulated Amortization Net Carrying Amount Intangible assets subject to amortization: Technology 10 $ 32,539 $ (5,685) $ 26,854 Customer relationships 9-12 1,984 (544) 1,440 Tradename 3 111 (80) 31 Non-compete 1 208 (208) - Total intangible assets subject to amortization 34,842 (6,517) 28,325 Indefinite-lived intangible assets: Tradename Indefinite 3,601 - 3,601 Total indefinite-lived intangible assets 3,601 - 3,601 Total intangible assets $ 38,443 $ (6,517) $ 31,926 December 31, 2015 Useful Life Gross Accumulated Net Carrying Amount Technology 10 $ 32,539 $ (4,057) $ 28,482 Customer relationships 9-12 1,984 (449) 1,535 Tradename 3 111 (62) 49 Non-compete 1 208 (208) - $ 34,842 $ (4,776) $ 30,066 Indefinite-lived intangible assets: Tradename Indefinite 3,601 - 3,601 Total indefinite-lived intangible assets 3,601 - 3,601 Total intangible assets $ 38,443 $ (4,776) $ 33,667 Amortization expense attributable to intangible assets for the three months ended June 30, 2016 and 2015 was $ 870,000 415,000 1.7 629,000 3.5 3.5 3.4 3.2 3.1

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued Expenses June 30, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 1,734 $ 2,118 Professional fees 715 671 Royalty fees 407 52 Deferred revenue 51 92 Other 135 138 Total accrued expenses and other current liabilities $ 3,042 $ 3,071

Debt

Debt	6 Months Ended
	Jun. 30, 2016
Debt Instruments [Abstract]
Long-term Debt [Text Block]	8. Debt Senior Secured Term Loan Facility On May 29, 2015, simultaneously with and related to the closing of the Celleration acquisition, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 four-year accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75% is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date 10.75 1.3 72,000 144,000 26,000 In connection with the entry into the Credit Agreement, a five-year warrant 750,000 0.001 5.5138 2.7 159,000 284,000 59,000 The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan up to 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions. The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000. The Credit Agreement contains customary affirmative and negative covenants and events of default for a secured financing arrangement, including limitations on additional indebtedness, liens, asset sales and acquisitions, as well as minimum trailing twelve-month revenue levels and minimum cash requirements, among others. In addition to other customary events of default, any termination of that certain License, Marketing and Development Agreement between the Company and CCT, as amended, will constitute an event of default under the Credit Agreement. On June 30, 2016, the Company entered into a Consent Under Credit Agreement (the “Consent Agreement”) with Perceptive pursuant to which Perceptive consented to the Purchase Agreement with BSN (see Note 4 – Discontinued Operations ), provided that the Company agreed to pay $ 1,800,000 1,747,573 52,427 June 30, December 31, 2016 2015 Long-term debt $ 15,500 $ 15,500 Unamortized debt issuance and discount costs (2,944) (3,374) Total $ 12,556 $ 12,126 Less: Current portion of long-term debt 1,780 - Long-term debt, net $ 10,776 $ 12,126

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies License Agreement On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 600,000 150,000 125,000 300,000 250,000 299,000 497,000 Agreements for Human Placental Based Products Human Longevity, Inc. In January 2016, Human Longevity, Inc.’s (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). CCT assigned and HLI assumed the agreements referred to below. In April 2016, the Company entered into a Supply Agreement with HLI, pursuant to which HLI will supply the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix (CTM). The Company expects to initiate sales and marketing efforts for Interfyl™ Human Connective Tissue Matrix in 2016. License Agreement with CCT In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) with Anthrogenesis Corporation, d/b/a Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”), pursuant to which CCT granted the Company an exclusive, royalty-bearing license in its intellectual property for certain placental based products, including ECM, a purified extracellular matrix that is derived from the human placenta, and Biovance®, CCT’s proprietary wound coverings produced from decellularized, dehydrated human amniotic membrane, to develop and commercialize ECM and Biovance in the United States. The Company is required to pay CCT annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. The initial term of the License Agreement ends on November 14, 2023, unless sooner terminated pursuant to the termination rights under the License Agreement, and will extend for additional two-year terms unless either party gives written notice within a specified period prior to the end of a term. The License Agreement may be terminated (i) by CCT if the Company or any of its affiliates challenges the validity, enforceability or scope of certain enumerated CCT patents anywhere in the world; (ii) by either party if there is a final decree that a licensed product infringed on the intellectual property of a third party; (iii) by either party for breach of the License Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. In addition, the License Agreement is terminable on a product-by-product basis, and not with respect to the entire License Agreement (i) by CCT in the second year of the License Agreement, and by either CCT or the Company in the third year of the License Agreement and beyond, if the Company fails to meet certain sales thresholds and (ii) by either party upon written notice if outside legal counsel recommends discontinuance of commercialization of a product because of significant safety, legal, or economic risk as a result of a claim, demand or action or as a result of a change in the interpretation of law by a governmental or regulatory authority. The License Agreement also contains mutual confidentiality and indemnification obligations for the Company and CCT. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. The Company is still evaluating the development path for ECM based on continued consultation with the FDA. Any further development and commercialization is unlikely at this time. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix known as Interfyl™ Human Connective Tissue Matrix. Supply Agreements with CCT In November 2013, the Company also entered into a Supply Agreement (the “Biovance Supply Agreement”) with CCT, pursuant to which CCT shall supply the Company with the Company’s entire requirements of Biovance for distribution and sale in the United States. The Biovance Supply Agreement will be terminated automatically upon the termination of the License Agreement and may otherwise be terminated (i) by CCT upon six months’ prior written notice, (ii) by the Company upon six months’ prior written notice if CCT fails to deliver at least a specified portion of a firm purchase order by the required delivery date specified in the order on at least a specified number of occasions in a specified period; (iii) by either party for breach of the Biovance Supply Agreement, if the breach is not cured within a specified period after receiving written notice of the breach; or (iv) by either party if the other party is the subject of insolvency proceedings, either voluntary or involuntary. On April 10, 2014, the Company and CCT entered into an amendment to the Biovance Supply Agreement in order to amend the pricing schedule. Operating Lease In January 2016, the Company entered into a lease for new office space to in Eden Prairie, Minnesota through 2023. The lease for the office currently utilized in Eden Prairie, Minnesota expires in April 2016. The remaining minimum lease payments for the newly leased space as of June 30, 2016 were approximately $ 585,000 Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of June 30, 2016.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	10. Stockholders’ Equity Common Stock On May 6, 2016, the Company held its 2016 annual meeting of stockholders. The stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 45,714,286 95,000,000 Stock-Based Compensation During the three and six months ended June 30, 2016, the Company recognized $ 1.4 3.1 47,000 129,000 1.3 3.0 2.3 4.3 90,000 182,000 2.2 4.1 5.7 1.5 Restricted Stock On February 9, 2016, the Company granted 324,561 474,000 On May 11, 2016, the Company granted 700,000 602,000 Stock Options Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Risk free interest rate 1.14%-1.60% 1.49%-2.11% 1.14%-2.06% 1.14%-1.60% Expected term (years) 5.04-6.50 5.04-6.50 5.04-6.50 5.00-6.50 Expected volatility 89.95 % 98.25 % 89.95 % 98.25 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the “simplified method” to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Number of Options Weighted Weighted Intrinsic Value Outstanding, December 31, 2015 6,230,549 $ 6.26 - $ - Granted 1,594,000 1.05 Exercised - - Forfeited (397,270) 4.03 Outstanding, June 30, 2016 7,427,279 $ 5.26 7.6 $ 151,625 Exerciseable, June 30, 2016 3,998,878 $ 6.24 6.5 $ 4,875 The weighted average estimated fair value per share of the options granted during the three and six months ended June 30, 2016 was $ 0.64 0.77 The weighted average estimated fair value per share of the options granted during the three and six months ended June 30, 2015 was $ 3.86 4.39

Related Party

Related Party	6 Months Ended
	Jun. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	11. Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director is a member of the Board of Directors. During the three and six months ended June 30, 2016, the Company incurred costs of approximately $ 53,000 258,000 28,000 5,000

Concentration of Risk

Concentration of Risk	6 Months Ended
	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	12. Concentration of Risk % of Total Revenue Accounts Receivable Customer 2016 2015 June 30, 2016 A 12 % 7 % 14 % B 7 % 10 % 6 % Revenue for the six months ended June 30, 2016 and 2015 from our largest customers was as follows: % of Total Revenue Customer 2016 2015 A 10 % 15 % B 7 % 10 %

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	13. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. On June 30, 2016, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 816,287 199,000 59.26 78.30 0.45 0.86 1.36 3.92 0.00 75,000 662,000 See Note 3 – Acquisitions for additional detail. Six Months Ended June 30, 2016 2015 Warrant Liabilities Beginning balance $ 861 $ 304 Change in fair value of warrant liability (662) 78 Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance $ 199 $ 3,034 Six Months Ended June 30, 2016 2015 Contingent Consideration Beginning balance $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (8,730) 373 Ending balance $ 3,151 $ 18,875 June 30, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 199 Contingent consideration - - 3,151 Total liabilities $ - $ - $ 3,350 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889 Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expected future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes The difference between the statutory income tax rate and the effective income tax rate is that the Company anticipates having a tax loss for the full fiscal 2016 year. During the three and six months ended June 30, 2015, the Company recorded an income tax benefit of approximately $ 1.4 1.4

Description of Business and B21

Description of Business and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, the condensed consolidated financial statements include all adjustments, which are of a normal recurring nature, necessary to present fairly the Company’s financial position as of June 30, 2016 and results of operations and cash flows for the three and six months ended June 30, 2016.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiary, AquaMed Technologies, Inc. All significant inter-company transactions and accounts have been eliminated in consolidation.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.
Liquidity [Policy Text Block]	As of June 30, 2016, the Company had cash and cash equivalents and working capital of approximately $ 12.6 14.9 10.5 2.6 1.4 The Company’s cash requirements have historically been for mergers and acquisitions, product development, clinical trials, marketing and sales activities, finance and administrative costs, capital expenditures and working capital. Since inception, the Company has incurred negative cash flows and has funded operations primarily from the sales of common stock and other securities. On June 30, 2016 the Company sold the rights to the sorbion product for total consideration of approximately $ 4.1 3.5 1.8 Due to the time delay between collection of revenues and the initial outlays for costs for acquiring rights to additional products, the hiring and training of sales agents and personnel, marketing, purchasing inventory, billing and collection of revenue, conducting a post market clinical trial for Biovance, servicing debt, and due diligence related to merger and acquisition activities, the Company expects to continue to have a cash outflow until it has a significant increase in revenue, achieves profitability or raises additional financing. If the Company is unable to achieve profitability, raise additional financing or extend the time or manner of the final installment of the contingent consideration, it will need to develop and implement an alternative plan to extend payables, reduce operating costs and/or scale back planned business operations until sufficient capital is raised to support its business plans. There can be no assurance that such a plan will be successful. In addition, the Company’s credit agreement requires it to meet certain financial covenants. Failure to observe or perform any covenant contained in the credit agreement would result in the event of default. If an event to default were to occur, payment of the remaining principal amount of approximately $ 13.7
Significant Accounting Policies and Estimates [Policy Text Block]	Significant Accounting Policies and Estimates The Company’s significant accounting policies are disclosed in Note 2 — Summary of Significant Accounting Policies
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the condensed consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The Company calculated the potential diluted earnings per share in accordance with ASC 260, as follows (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Numerator: Net income (loss) from continuing operations (numerator for basic and diluted earnings per share) $ 1,357 $ (7,261) $ (6,671) $ (15,071) Weighted average shares outstanding (denominator for basic earnings per share) 28,169,843 22,108,703 27,731,465 22,103,337 Effect of dilutive securities: Assumed vesting of restricted stock, treasury stock method 398,757 - - - Dilutive potential common shares 398,757 - - - Denominator for diluted earnings per share- weighted average shares and assumed potential common shares 28,568,600 22,108,703 27,731,465 22,103,337 Basic earnings (loss) from continuing operations per share $ 0.05 $ (0.33) $ (0.24) $ (0.68) Diluted earnings (loss) from continuing operations per share $ 0.05 $ (0.33) $ (0.24) $ (0.68)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares for the following periods because their inclusion would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Options 7,427,279 6,073,740 7,427,279 6,073,740 Warrants 3,365,407 3,372,550 3,365,407 3,372,550 Non-vested restricted stock 460,001 784,076 1,480,041 784,076 Total potentially dilutive shares 11,252,687 10,230,366 12,272,727 10,230,366

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2016
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma results of operations for the three and six months ended June 30, 2015 are as follows (in thousands, except per share amounts): Three Months Ended Six Months Ended Revenues $ 4,362 $ 8,138 Net loss $ (10,835) $ (21,128) Net loss per share $ (0.43) $ (0.84)

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the three and six months ended June 30, 2016, the Company recorded a gain of approximately $ 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations are presented in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Revenue, net of returns, allowances and discounts $ 1,023 $ 648 $ 1,709 $ 1,201 Cost of revenues 348 184 536 358 Gross profit 675 464 1,173 843 Selling, general and administrative 171 193 323 423 Income from discontinued operations, net of tax 504 271 850 420 Summarized assets and liabilities of discontinued operations are presented in the following table (in thousands): June 30, December 31, 2016 2015 Accounts receivable, net $ 533 $ 457 Inventory, net - 858 Total current assets 533 1,315 Intangible assets, net - 227 Total assets 533 1,542 Accounts payable 48 44 Accrued expenses and other current liabilities 63 59 Total current liabilities $ 111 $ 103

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (in thousands): June 30, December 31, 2016 2015 Raw materials $ 213 $ 241 Work in process 255 228 Finished goods 2,722 1,865 Less: Inventory reserve for excess and slow moving inventory (62) (59) Total $ 3,128 $ 2,275

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets are as follows (in thousands): June 30, 2016 Useful Life Gross Accumulated Amortization Net Carrying Amount Intangible assets subject to amortization: Technology 10 $ 32,539 $ (5,685) $ 26,854 Customer relationships 9-12 1,984 (544) 1,440 Tradename 3 111 (80) 31 Non-compete 1 208 (208) - Total intangible assets subject to amortization 34,842 (6,517) 28,325 Indefinite-lived intangible assets: Tradename Indefinite 3,601 - 3,601 Total indefinite-lived intangible assets 3,601 - 3,601 Total intangible assets $ 38,443 $ (6,517) $ 31,926 December 31, 2015 Useful Life Gross Accumulated Net Carrying Amount Technology 10 $ 32,539 $ (4,057) $ 28,482 Customer relationships 9-12 1,984 (449) 1,535 Tradename 3 111 (62) 49 Non-compete 1 208 (208) - $ 34,842 $ (4,776) $ 30,066 Indefinite-lived intangible assets: Tradename Indefinite 3,601 - 3,601 Total indefinite-lived intangible assets 3,601 - 3,601 Total intangible assets $ 38,443 $ (4,776) $ 33,667

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 1,734 $ 2,118 Professional fees 715 671 Royalty fees 407 52 Deferred revenue 51 92 Other 135 138 Total accrued expenses and other current liabilities $ 3,042 $ 3,071

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2016
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following (in thousands): June 30, December 31, 2016 2015 Long-term debt $ 15,500 $ 15,500 Unamortized debt issuance and discount costs (2,944) (3,374) Total $ 12,556 $ 12,126 Less: Current portion of long-term debt 1,780 - Long-term debt, net $ 10,776 $ 12,126

Stockholders' Equity (Tables)

Stockholders' Equity (Tables) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Risk free interest rate 1.14%-1.60% 1.49%-2.11% 1.14%-2.06% 1.14%-1.60% Expected term (years) 5.04-6.50 5.04-6.50 5.04-6.50 5.00-6.50 Expected volatility 89.95 % 98.25 % 89.95 % 98.25 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the six months ended June 30, 2016 is presented below: Number of Options Weighted Weighted Intrinsic Value Outstanding, December 31, 2015 6,230,549 $ 6.26 - $ - Granted 1,594,000 1.05 Exercised - - Forfeited (397,270) 4.03 Outstanding, June 30, 2016 7,427,279 $ 5.26 7.6 $ 151,625 Exerciseable, June 30, 2016 3,998,878 $ 6.24 6.5 $ 4,875

Concentration of Risk (Tables)

Concentration of Risk (Tables)	6 Months Ended
	Jun. 30, 2016
Risks and Uncertainties [Abstract]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Revenue for the three months ended June 30, 2016 and 2015, and accounts receivable as of June 30, 2016 from the Company’s largest customers were as follows: % of Total Revenue Accounts Receivable Customer 2016 2015 June 30, 2016 A 12 % 7 % 14 % B 7 % 10 % 6 % Revenue for the six months ended June 30, 2016 and 2015 from our largest customers was as follows: % of Total Revenue Customer 2016 2015 A 10 % 15 % B 7 % 10 %

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): Six Months Ended June 30, 2016 2015 Warrant Liabilities Beginning balance $ 861 $ 304 Change in fair value of warrant liability (662) 78 Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance $ 199 $ 3,034 Six Months Ended June 30, 2016 2015 Contingent Consideration Beginning balance $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (8,730) 373 Ending balance $ 3,151 $ 18,875
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and liabilities measured at fair value on a recurring or nonrecurring basis are as follows (in thousands): June 30, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 199 Contingent consideration - - 3,151 Total liabilities $ - $ - $ 3,350 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889

Description of Business and B32

Description of Business and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	May 29, 2015	Dec. 31, 2014
Cash and Cash Equivalents, at Carrying Value, Total		$ 12,572	$ 35,760	$ 26,080		$ 16,771
Working Capital		14,900			$ 300
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total		(10,451)	(12,358)
Payments to Acquire Businesses, Gross		2,573	$ 0
Business Combination, Contingent Consideration, Liability, Current		1,359		2,573
Long-term Debt, Total		12,556		$ 12,126
Consideration for intangible assets, net		3,500
Repayments of Debt		1,800
Intellectual Property [Member]
Consideration for intangible assets, net		$ 4,100
Scenario, Forecast [Member]
Consideration for intangible assets, net	$ 3,500

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income (loss) from continuing operations (numerator for basic and diluted earnings per share)	$ 1,357	$ (7,261)	$ (6,671)	$ (15,071)
Weighted average shares outstanding (denominator for basic earnings per share)	28,169,843	22,108,703	27,731,465	22,103,377
Effect of dilutive securities:
Assumed vesting of restricted stock, treasury stock method	398,757	0	0	0
Dilutive potential common shares	398,757	0	0	0
Denominator for diluted earnings per share- weighted average shares and assumed potential common shares	28,568,600	22,108,703	27,731,465	22,103,377
Basic earnings (loss) from continuing operations per share	$ 0.05	$ (0.33)	$ (0.24)	$ (0.68)
Diluted earnings (loss) from continuing operations per share	$ 0.05	$ (0.33)	$ (0.24)	$ (0.68)

Net Loss Per Common Share (De34

Net Loss Per Common Share (Details 1) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	11,252,687	10,230,366	12,272,727	10,230,366
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,427,279	6,073,740	7,427,279	6,073,740
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,365,407	3,372,550	3,365,407	3,372,550
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	460,001	784,076	1,480,041	784,076

Acquisitions (Details)

Acquisitions (Details) - Acquisition of Celleration, Inc [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Business Acquisition [Line Items]
Revenues	$ 4,362	$ 8,138
Net loss	$ (10,835)	$ (21,128)
Net loss per share	$ (0.43)	$ (0.84)

Acquisitions (Details Textual)

Acquisitions (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 31, 2016	May 29, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Revenues, Total			$ 4,467	$ 2,488	$ 8,424	$ 4,049
Working Capital		$ 300	14,900		14,900
Business Combination, Contingent Consideration, at Fair Value					0	15,570
Payments to Acquire Businesses, Gross					2,573	0
Business Combination, Contingent Consideration, Liability, Noncurrent			1,792		1,792			$ 14,455
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(9,092)	$ 265	(8,730)	$ 373
Continget Consideration Installment Two [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 2,800		2,800
MIST Therapy [Member]
Business Acquisition [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets								3.5
MIST Therapy [Member] | Scenario, Forecast [Member]
Business Acquisition [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets							3.5
2015 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total					10,200
2014 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total					$ 8,700
Acquisition of Celleration, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition Initial Cash Payment		15,500
Business Combination, Contingent Consideration, at Fair Value		15,600
Business Combination, Consideration Transferred, Total		$ 46,300
Acquisition of Celleration, Inc [Member] | Installment One [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	986,000
Payments to Acquire Businesses, Gross	$ 2,600
Fair Value Inputs, Discount Rate					12.50%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,600
Acquisition of Celleration, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions		3,168,229

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Proceeds from sale
Consideration for inventory			$ 603
Consideration for intangible assets			3,500
Total Consideration			4,103
Less: Net book value of assets sold to BSN
Inventory, net	$ (603)		(603)
Intangibles, net	(189)		(189)
Total net book value of assets	(792)		(792)
Gain on sale of assets	$ 3,311	$ 0	$ 3,311	$ 0

Discontinued Operations (Deta38

Discontinued Operations (Details 1) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net of returns, allowances and discounts	$ 1,023	$ 648	$ 1,709	$ 1,201
Cost of revenues	348	184	536	358
Gross profit	675	464	1,173	843
Selling, general and administrative	171	193	323	423
Income from discontinued operations, net of tax of $0 for the three and six months ended June 30, 2016 and 2015	$ 504	$ 271	$ 850	$ 420

Discontinued Operations (Deta39

Discontinued Operations (Details 2) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	$ 533	$ 457
Inventory, net	0	858
Total current assets	533	1,315
Intangible assets, net	0	227
Total assets	533	1,542
Accounts payable	48	44
Accrued expenses and other current liabilities	63	59
Total current liabilities	$ 111	$ 103

Discontinued Operations (Deta40

Discontinued Operations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses and Interests in Affiliates			$ 3,500,000
Contractual Obligation	$ 900,000		900,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	3,311,000	$ 0	3,311,000	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	0	0	0	0
Sales Revenue, Services, Other			100,000
Amortization of Intangible Assets	870,000	$ 415,000	1,700,000	629,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	$ 3,300,000		3,300,000
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets			$ 38,000	$ 38,000

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 213	$ 241
Work in process	255	228
Finished goods	2,722	1,865
Less: Inventory reserve for excess and slow moving inventory	(62)	(59)
Total	$ 3,128	$ 2,275

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 38,443	$ 38,443
Accumulated Amortization	(6,517)	(4,776)
Net Carrying Amount	31,926	33,667
Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,601	3,601
Accumulated Amortization	0	0
Net Carrying Amount	3,601	3,601
Intangible assets subject to amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	34,842	34,842
Accumulated Amortization	(6,517)	(4,776)
Net Carrying Amount	$ 28,325	$ 30,066
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	10 years	10 years
Gross Amount	$ 32,539	$ 32,539
Accumulated Amortization	(5,685)	(4,057)
Net Carrying Amount	26,854	28,482
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	1,984	1,984
Accumulated Amortization	(544)	(449)
Net Carrying Amount	$ 1,440	$ 1,535
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	9 years	9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	12 years	12 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	3 years	3 years
Gross Amount	$ 111	$ 111
Accumulated Amortization	(80)	(62)
Net Carrying Amount	31	49
Tradename [Member] | Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	3,601	3,601
Accumulated Amortization	0	0
Net Carrying Amount	$ 3,601	$ 3,601
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life	1 year	1 year
Gross Amount	$ 208	$ 208
Accumulated Amortization	(208)	(208)
Net Carrying Amount	$ 0	$ 0

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 870,000	$ 415,000	$ 1,700,000	$ 629,000
Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year	3,500,000		3,500,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	3,500,000		3,500,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	3,400,000		3,400,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	3,200,000		3,200,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	$ 3,100,000		$ 3,100,000

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 1,734	$ 2,118
Professional fees	715	671
Royalty fees	407	52
Deferred revenue	51	92
Other	135	138
Total accrued expenses and other current liabilities	$ 3,042	$ 3,071

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt	$ 15,500	$ 15,500
Unamortized debt issuance and discount costs	(2,944)	(3,374)
Total	12,556	12,126
Less: Current portion of long-term debt	1,780	0
Long-term debt, net	$ 10,776	$ 12,126

Debt (Details Textual)

Debt (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	May 29, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138		$ 5.5138
Derivative Liability	$ 199,000	$ 3,034,000	$ 199,000	$ 3,034,000	$ 861,000		$ 304,000
Amortization of Debt Discount (Premium)			$ 428,000	85,000
Warrant Expiration Period			five-year warrant
Common Stock Purchased By Warrants Issued			750,000
Proceeds from Divestiture of Businesses and Interests in Affiliates			$ 3,500,000
Repayments of Debt			$ 1,800,000
Exit fee payment, Credit Agreement Description			The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 1% of the outstanding principal balance immediately prior to the final payment and $100,000.
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	199,000		$ 199,000		$ 861,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability	2,700,000		2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs	72,000	26,000	144,000	26,000
Amortization of Debt Discount (Premium)	$ 159,000	$ 59,000	284,000	$ 59,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 15,500,000
Debt Issuance Costs1			$ 1,300,000
Debt Instrument, Interest Rate Terms			accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Term			4 years
Debt Instrument, Payment Terms			is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument Prepayment Terms			The Credit Agreement requires the Company to prepay the outstanding principal amount of the term loan up to 100% of the net cash proceeds received from specified asset sales, issuances or sales of equity and incurrences of borrowed money indebtedness, subject to certain exceptions.
Debt Instrument, Interest Rate During Period			10.75%
Payments for Prepayment Penalties			$ 52,427
Proceeds from Divestiture of Businesses and Interests in Affiliates			1,800,000
Repayments of Debt			$ 1,747,573

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Accounts Payable, Current		$ 2,117,000		$ 2,117,000		$ 2,594,000
Operating Leases, Future Minimum Payments Due, Next Twelve Months		585,000		585,000
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accounts Payable, Current		299,000		299,000		$ 497,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		600,000		600,000
Royalty Expense		$ 150,000	$ 125,000	$ 300,000	$ 250,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Employee Stock Option [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	89.95%	98.25%	89.95%	98.25%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.14%	1.49%	1.14%	1.14%
Expected term (years)	5 years 14 days	5 years 14 days	5 years 14 days	5 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.60%	2.11%	2.06%	1.60%
Expected term (years)	6 years 6 months	6 years 6 months	6 years 6 months	6 years 6 months

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Employee Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	6,230,549
Number of Options, Granted (in shares)	1,594,000
Number of Options, Exercised (in shares)	0
Number of Options, Forfeited (in shares)	(397,270)
Number of Options, Outstanding at End of the period (in shares)	7,427,279	6,230,549
Number of Options, Exercisable, June 30, 2016 (in shares)	3,998,878
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 6.26
Weighted Average Exercise Price, Granted (in dollars per share)	1.05
Weighted Average Exercise Price, Exercised (in dollars per share)	0
Weighted Average Exercise Price, Forfeited (in dollars per share)	4.03
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	5.26	$ 6.26
Weighted Average Exercise Price, Exercisable June 30, 2016 (in dollars per share)	$ 6.24
Weighted Average Remaining Life In Years, Outstanding, June 30, 2016 (Years)	7 years 7 months 6 days	0 years
Weighted Average Remaining Life In Years, Exercisable, Exercisable, June 30, 2016 (Years)	6 years 6 months
Intrinsic Value, Outstanding, June 30, 2016	$ 151,625	$ 0
Intrinsic Value, Exercisable, June 30, 2016	$ 4,875

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	May 11, 2016	Feb. 09, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	May 06, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 1,400,000	$ 2,300,000	$ 3,100,000	$ 4,300,000
Common Stock, Shares Authorized			95,000,000		95,000,000		45,714,286	95,000,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.64	$ 3.86	$ 0.77	$ 4.39
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 47,000	$ 90,000	$ 129,000	$ 182,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			1,300,000	$ 2,200,000	3,000,000	$ 4.1
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total			$ 5,700,000		$ 5,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					1 year 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	700,000	324,561
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value	$ 602,000	$ 474,000

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 53,000	$ 258,000
Accounts Payable, Related Parties	$ 28,000	$ 28,000	$ 5,000

Concentration of Risk (Details)

Concentration of Risk (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Sales Revenue, Net [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	12.00%	7.00%	10.00%	15.00%
Sales Revenue, Net [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	7.00%	10.00%	7.00%	10.00%
Accounts Receivable [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	14.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	6.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 861	$ 304
Change in fair value of warrant liability	(662)	78
Initial fair value of contingent consideration	0	15,570
Value of warrants issued	0	2,683
Value of warrants exercised	0	(31)
Ending balance	199	3,034
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	17,028	2,932
Change in fair value of warrant liability	(8,730)	373
Initial fair value of contingent consideration	0	15,570
Payments of contingent consideration	(5,147)	0
Ending balance	$ 3,151	$ 18,875

Fair Value Measurement (Detai54

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Liabilities:
Warrant liabilities	$ 199	$ 861	$ 3,034	$ 304
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	199	861
Contingent consideration	3,151	17,028
Total liabilities	$ 3,350	$ 17,889

Fair Value Measurement (Detai55

Fair Value Measurement (Details Textual) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$ 75,000	$ 662,000
Derivative Liability	199,000	199,000	$ 861,000	$ 3,034,000	$ 304,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability	199,000	$ 199,000	$ 861,000
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Dividend Rate		0.00%
Warrants To Purchase Common Stock		816,287
Derivative Liability	$ 199,000	$ 199,000
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		78.30%
Fair Value Assumptions, Risk Free Interest Rate		0.86%
Fair Value Assumptions, Expected Term		3 years 11 months 1 day
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		59.26%
Fair Value Assumptions, Risk Free Interest Rate		0.45%
Fair Value Assumptions, Expected Term		1 year 4 months 10 days

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	May 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Taxes [Line Items]
Income tax (expense) benefit		$ (3)	$ 1,440	$ (6)	$ 1,437
Deferred Taxes, Business Combination, Valuation Allowance, Available to Reduce Income Tax Expense	$ 1,400